Keywords: مقاومت دارویی; Phosphoproteomics; Kinase inhibitors; Drug resistance; Pazopanib; Dasatinib; Cell signalling;
مقالات ISI مقاومت دارویی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مقاومت دارویی; Gene chip; Drug resistance; Sensibility; Specificity; Pulmonary tuberculosis;
Keywords: مقاومت دارویی; ALIX; (ALG-2)-interacting protein X; ARF6; ADP ribosylation factor 6; DC; dendritic cell; DHA; docosahexaenoic acid; EPA; eicosapentaenoic acid; ESCRT; endosomal sorting complexes required for transport; EV; extracellular microvesicle; EX; exosome; MDSC;
Keywords: مقاومت دارویی; physiology-based pharmacokinetics; pharmacokinetics; drug resistance; onychomycosis; in silico modeling;
Keywords: مقاومت دارویی; Cancer stem cell; Drug resistance; Liposome; Drug delivery system; Clinical translation; Immunotherapy;
Keywords: مقاومت دارویی; Mycobacterium tuberculosis; Drug resistance; TB targets; Hit-to-lead optimization; Prospective drugs;
Keywords: مقاومت دارویی; Gastroenteritis; Salmonella; Bacteremia; Drug resistance; Cephalosporins;
Keywords: مقاومت دارویی; Histopathology; Typical granulomatous lesions; M. fortuitum; Drug resistance;
Keywords: مقاومت دارویی; Drug resistance; Inflammation; Immune response; Lymphoma; Microenvironment;
Keywords: مقاومت دارویی; Drug resistance; Diagnostics; Regimen selection; Treatment outcomes; Cost effectiveness;
Keywords: مقاومت دارویی; Metabolic acidosis; Hypoxia; Enzyme activation; Tumorigenesis; Drug resistance;
Keywords: مقاومت دارویی; Epilepsy; Drug resistance; Juvenile myoclonic epilepsy; Temporal lobe epilepsy;
Keywords: مقاومت دارویی; Mycobacterium tuberculosis; Spoligotyping; Beijing; MDR; Drug resistance;
Keywords: مقاومت دارویی; Tumor heterogeneity; Precision medicine; Genetic variations; Cancer; Drug resistance; Biomarker;
Keywords: مقاومت دارویی; Next-generation sequencing; Non-small-cell lung cancer; Diagnosis; Therapy; Drug resistance;
Keywords: مقاومت دارویی; Cancer; Targeted therapy; Drug resistance;
Keywords: مقاومت دارویی; EGFR; Epidermal growth factor receptor; TP53; Tumor protein p53; KRAS; Kirsten rat carcoma viral oncogene; ALK; Anaplastic lymphoma kinase; RTK; Protein receptor tyrosine kinase; TKI; Tyrosine kinase inhibitor; PI3K; Phosphatidylinositol 3-kinase; NSCLC;
Keywords: مقاومت دارویی; Tumor angiogenesis; Tumor homing peptide; Phage display; Drug resistance; Integrins;
Keywords: مقاومت دارویی; Vinca alkaloids; Lung cancer; Drug resistance;
Keywords: مقاومت دارویی; Nitrofurans; Antitubercular; Drug resistance; Patient-derived strains; Multicomponent chemistry; N-amino lactams;
Keywords: مقاومت دارویی; Mycoplasma pneumoniae;; Whole-genome sequencing; Drug resistance; Macrolide-specific efflux pump; Efflux pump inhibitors;
Keywords: مقاومت دارویی; High-throughput screening; Drug target; Drug interactions; Genomics; Drug resistance;
Keywords: مقاومت دارویی; Binary deoxyribozyme; Multiplex PCR; Diagnostics; Tuberculosis; Drug resistance; Nucleic acid sensors;
Raman spectroscopy differentiates between sensitive and resistant multiple myeloma cell lines
Keywords: مقاومت دارویی; Multiple myeloma cell line; Drug resistance; Rapid identification; Raman spectroscopy; PCA analysis;
Keywords: مقاومت دارویی; Non-tuberculous mycobacteria; Mycobacterium abscessus; Mycobacterium massiliense; Macrolides; Drug resistance;
Keywords: مقاومت دارویی; IC50; 50% inhibitory concentration; MIC; minimum inhibitory concentration; MIC50; 50% minimum inhibitory concentration; SAR; structure activity relationship; MABA; microplate alamar blue assay; Flavonoids; Polyphenols; Oral candidiasis; Drug resistance; A
Keywords: مقاومت دارویی; Leishmania donovani; Drug resistance; Paromomycin; Transcriptome; ABC transporters; Nitric oxide; Visceral leishmaniasis;
Keywords: مقاومت دارویی; Lymphoma; Non-Hodgkin lymphoma; Drug resistance; Vincristine; Quercetin;
Keywords: مقاومت دارویی; Resveratrol; Natural product; Infectious diseases; Drug resistance;
Keywords: مقاومت دارویی; Epidemiology; Gram-negative bacteria; Australia; Drug resistance;
Keywords: مقاومت دارویی; Refractory epilepsy; Animal models; P-glycoprotein; Drug resistance; 3-Mercaptopropionic acid; Mice;
A perspective on general direction and challenges facing antimicrobial peptides
Keywords: مقاومت دارویی; Antimicrobial peptides (AMPs); Drug resistance; Biomaterials; Antimicrobial materials; Antimicrobial mechanism;
Keywords: مقاومت دارویی; Nanoparticles; Drug resistance; Nanotechnology; Antimicrobials; Nanomedicine;
Keywords: مقاومت دارویی; Antimicrobial agents; Drug resistance; West Africa;
Keywords: مقاومت دارویی; Pancreatic ductal adenocancinoma; Gemcitabine; Drug resistance; Genes; MicroRNAs;
Keywords: مقاومت دارویی; Citral; MRSA; Drug resistance; Synergistic interaction; Membrane damage; Nor; norfloxacin; SA; Staphylococcus aureus; FICI; fractional inhibitory concentration index; CFU; colony forming unit; MIC; minimum inhibitory concentration; h; hour; MRSA; methicil
Keywords: مقاومت دارویی; VL; visceral leishmaniasis; PKDL; post-kala-azar dermal leishmaniasis; WHO; World Health Organization; TDR; Tropical Disease Research; HGPRT; hypoxanthine-guanine phosphoribosyltransferase; CDKs; cyclin dependent kinases; Leishmaniasis; Dose regimen; Drug
Keywords: مقاومت دارویی; Polymeric prodrug; Pancreatic stellate cells; SN38; GDC-0449; Pancreatic cancer; Drug resistance;
Keywords: مقاومت دارویی; Cancer metabolism; Drug resistance; New metabolically-targeted agents; Pancreatic cancer;
Keywords: مقاومت دارویی; Chemotherapy; Drug resistance; Natural products; Sesquiterpenoids; Toxicology; ACE; angiotensin I-converting enzyme; ACT; artemisinin-based combination therapy; Akt; AKT serine/threonine kinase, v-akt murine thymoma viral oncogene homologue; AMP; adenosin
Keywords: مقاومت دارویی; Liposomal complexes; Hypoxia; Drug resistance; PFOB; NSCLC;
Keywords: مقاومت دارویی; Leishmania donovani; Clinical isolates; Drug resistance; Antibodies;
Keywords: مقاومت دارویی; Intensive care unit; Infection control; Transmission; Drug resistance;
Keywords: مقاومت دارویی; Malaria; Plasmodium falciparum; Antimalarial drugs; Anopheles; Drug resistance; Nanotechnology; Silver nanoparticles; Nanocarriers;
Keywords: مقاومت دارویی; Haloduracin; Chloramphenicol; Combination therapy; Drug resistance; Topical antibiotics;
Keywords: مقاومت دارویی; Delivery; Drug resistance; Europe; Health service delivery; Latent tuberculosis; migration; Multidrug-resistant tuberculosis; Screening; Tuberculosis;
Keywords: مقاومت دارویی; Drug resistance; Epidermalgrowth factor receptor mutation; ALK rearrangement; Small cell carcinoma; Transformation; TKIs treatment;
Keywords: مقاومت دارویی; Colorectal cancer; Heterogeneity; Anti-EGFR therapies; Drug resistance;
Keywords: مقاومت دارویی; TB; tuberculosis; MTB; Mycobacterium tuberculosis; MDR-TB; multi-drug resistant tuberculosis; XDR-TB; extensively drug resistant tuberculosis; TDR-TB; totally drug resistant tuberculosis; INH; isoniazid; WHO; World Health Organization; RIF; rifampicin; PZ
Keywords: مقاومت دارویی; Anthracyclines; Deacetylase inhibitors; Drug resistance; Proteasome activity; Proteasome inhibitors;